Edge Therapeutics Inc. could cut to the front of the line in aneurysmal subarachnoid hemorrhage (aSAH) therapy with its polymeric microparticle form of the calcium channel blocker nimodipine, EG-1962, advancing into the second cohort of a phase I/II trial.